Key Insights

• Nuvectis Pharma's significant insider ownership suggests inherent interests in company's expansion

• The top 4 shareholders own 54% of the company

• Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company

If you want to know who really controls Nuvectis Pharma, Inc. (NASDAQ:NVCT), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are individual insiders with 67% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

With such a notable stake in the company, insiders would be highly incentivised to make value accretive decisions.

Let's delve deeper into each type of owner of Nuvectis Pharma, beginning with the chart below.

Check out our latest analysis for Nuvectis Pharma

What Does The Institutional Ownership Tell Us About Nuvectis Pharma?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Nuvectis Pharma. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Nuvectis Pharma's earnings history below. Of course, the future is what really matters.

We note that hedge funds don't have a meaningful investment in Nuvectis Pharma. Looking at our data, we can see that the largest shareholder is the CEO Ron Bentsur with 17% of shares outstanding. With 15% and 14% of the shares outstanding respectively, Charles Mosseri-Marlio and Charles Marlio are the second and third largest shareholders.

To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Nuvectis Pharma

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.